A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 1,601–1,700 of 3,965
Kacprzak, A., Tomkowski, W. Z., & Szturmowicz, M. (2023) · Diagnostics · doi:10.3390/diagnostics13142354 · Cited by 24
“Anti-fibrotic drugs are used to delay disease progression in IPF [48,49] and other fibrotic lung diseases progressing despite immunomodulatory therapy [50,51].”
BackgroundRamírez-Hernández, A. A., Reyes-Jiménez, E., Velázquez-Enríquez, J. M., Santos-Álvarez, J. C., Soto-Guzmán, A., Castro‐Sánchez, L., Tapia-Pastrana, G., Aguilar, H. T., Vásquez-Garzón, V. R., & Baltiérrez‐Hoyos, R. (2023) · Cells · doi:10.3390/cells12141852 · Cited by 21
Montesi, S. B., Gómez, C. R., Beers, M. F., Brown, R., Chattopadhyay, I., Flaherty, K. R., Garcia, C. K., Gomperts, B. N., Hariri, L. P., Hogaboam, C. M., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202307-1154ws · Cited by 21
Kamio, K., Usuki, J., Azuma, A., Matsuda, K., Ishii, T., Inomata, M., Hayashi, H., Kokuho, N., Fujita, K., Saito, Y., et al. (2015) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2015.03.001 · Cited by 18
Huang, X., Wang, W., Yuan, H., Sun, J., Li, L., Wu, X., Luo, J., & Gu, Y. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.239.251 · Cited by 19
The safety of new drug treatments for idiopathic pulmonary fibrosis
Fletcher, S., Jones, M. G., Spinks, K., Sgalla, G., Marshall, B. G., Limbrey, R., & Richeldi, L. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1218470 · Cited by 20
Hamano, Y., Kida, H., Ihara, S., Murakami, A., Yanagawa, M., Ueda, K., Honda, O., Tripathi, L. P., Arai, T., Hirose, M., et al. (2017) · Scientific Reports · doi:10.1038/srep43201 · Cited by 18
Kadoch, M. A., Kitich, A., Alqalyoobi, S., LaFond, E., Foster, E. E., Juarez, M. M., Mendez, C., Smith, T. W., Wong, G. B., Boyd, W. D., et al. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.02.017 · Cited by 19
Nyilas, S., Schreder, T., Singer, F., Poellinger, A., Geiser, T., Latzin, P., & Funke, M. (2018) · Respirology · doi:10.1111/resp.13294 · Cited by 21
Chung, J. H., & Goldin, J. G. (2018) · Lung · doi:10.1007/s00408-018-0143-5 · Cited by 19
Perelas, A., Glennie, J., van Kerkhove, K., Li, M., Scheraga, R. G., Olman, M. A., & Culver, D. A. (2019) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2019.101839 · Cited by 18
“The treatment of idiopathic pulmonary fibrosis (IPF) has been revolutionized by the introduction of antifibrotic therapy, but medication intolerance is common and often necessitates dose reduction or discontinuation [1, 2].”
BackgroundMethodPamrevlumab in idiopathic pulmonary fibrosis
Wells, A. U. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30339-x · Cited by 19
Majewski, S., Białas, A. J., Buchczyk, M., Gomółka, P., Górska, K., Jagielska-Len, H., Jarzemska, A., Jassem, E., Jastrzębski, D., Kania, A., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1162-6 · Cited by 20
Sadeleer, L. D., Goos, T., Yserbyt, J., & Wuyts, W. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061722 · Cited by 20
“In the ASCEND trial [5], these data were confirmed; moreover, the composite secondary endpoint of a significant increase in dyspnea scoring or death was reported in only 36% of placebo cases.”
MethodRictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis
Inomata, M., Kamio, K., Azuma, A., Matsuda, K., Usuki, J., Morinaga, A., Tanaka, T., Kashiwada, T., Atsumi, K., Hayashi, H., et al. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112416 · Cited by 20
Yamagata, A., Arita, M., Tachibana, H., Tokioka, F., Sugimoto, C., Sumikawa, H., Tanaka, T., Yasui, H., Fujisawa, T., Nakamura, Y., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01726-8 · Cited by 21
Management of Idiopathic Pulmonary Fibrosis
Salisbury, M. L., & Wijsenbeek, M. S. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.004 · Cited by 20
Gudmundsson, E., Zhao, A., Moğulkoç, N., Stewart, I. D., Jones, M. G., van Moorsel, C. H. M., Savaş, R., Brereton, C. J., van Es, H. W., Unat, Ö. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101009 · Cited by 23
César, E. C., López, L. L., Lara, E., Juan, M. V. H.-S., Romero, C. P., Palencia, J. L. R. S., Martín‐Montañez, E., & Garcia‐Fernandez, M. I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143167 · Cited by 21
Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
Albera, C., Verri, G., Sciarrone, F., Sitia, E., Mangiapia, M., & Solidoro, P. (2021) · Biomedicines · doi:10.3390/biomedicines9091237 · Cited by 17
Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy
Zhang, M., Gao, L., Ye, Y., & Li, X. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01187-2 · Cited by 19
Yang, Y., Ding, L., Bao, T., Li, Y., Ma, J., Li, Q., Gao, Z., Song, S., Wang, J., Zhao, J., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.770197 · Cited by 19
“However, the treatment of IPF also remains supportive presently, with pirfenidone and nintedanib being among the few drugs that have anti-PF effects (King et al., 2014; Flaherty et al., 2019).”
BackgroundJing, F., Chen, X., Xue, J., Huang, K., Xing, F., Hu, X., Peng, Y., & Liu, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.805432 · Cited by 19
“There are very limited therapeutic options for PF, except lung transplantation, two antifibrotic drugs, Pirfenidone and nintedanib have been approved by FDA for PF treatment (King et al., 2014; Karimi-Shah and Chowdhury, 2015).”
BackgroundInterstitial lung disease progression after genomic usual interstitial pneumonia testing
Chaudhary, S., Weigt, S. S., Neto, M. L. R., Benn, B. S., Pugashetti, J. V., Keith, R. C., Chand, A., Oh, S., Kheir, F. M., Ramalingam, V. S., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01245-2022 · Cited by 22
Kast, R. E., Skuli, N., Cos, S., Karpel‐Massler, G., Shiozawa, Y., Goshen, R., & Halatsch, M. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s139963 · Cited by 22
Paulín, F., Babini, A. M., Mamani, M. N., Mercado, J. F., & Caro, F. M. (2017) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.17002162 · Cited by 22
Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation
Gu, Y., Huang, B., Yang, Y., Qi, M., Lu, G., Xia, D., & Li, H. (2018) · Inflammation · doi:10.1007/s10753-018-0745-3 · Cited by 17
Borges, L. F., Jagadeesan, V. S., Goldberg, H. J., Gavini, S., Lo, W., Burakoff, R. B., Feldman, N., & Chan, W. W. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18023 · Cited by 18
“The use of pirfenidone is one novel therapeutic that has recently been shown to potentially reduce disease progression and improve survival.(22) However, since this novel treatment was not yet widely adopted at our center during the study period, this was not relevant to our cohort.”
BackgroundComorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
Millan‐Billi, P., Serra, C., Leon, A. A., & Castillo, D. (2018) · Medical Sciences · doi:10.3390/medsci6030059 · Cited by 25
“In a retrospective analysis [14] of three randomized controlled trials (Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With Idiopathic Pulmonary Fibrosis [PANTHER] [15], Anticoagulant Effectiveness in Idiopathic Pulmonary Fibrosis [ACE] [16], STEP [5]) anti-acid therapy was…”
Chen, M. C., Korth, C. C., Harnett, M. D., Elenko, E., & Lickliter, J. D. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1040 · Cited by 18
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
Sivaraman, L., Gill, M., Nelson, D. M., & Chadwick, K. D. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115846 · Cited by 17
Baughman, R. P., & James, W. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54429-0.00020-3 · Cited by 17
Han, S., Lee, J. E., Kang, S., So, M., Jin, H. K., Lee, J. H., Baek, S., Jun, H., Kim, T. Y., & Lee, Y. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae035 · Cited by 19
The future of clinical trials in idiopathic pulmonary fibrosis
Spagnolo, P., & Maher, T. M. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001099 · Cited by 20
Mooney, J. J., Jacobs, S. S., Lefebvre, E. A., Cosgrove, G. P., Clark, A., Turner, S., Decaris, M. L., Barnes, C. N., Jurek, M., Williams, B., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202409-969oc · Cited by 20
Vascular involvement in idiopathic pulmonary fibrosis
Mondoni, M., Rinaldo, R. F., Ryerson, C. J., Albrici, C., Baccelli, A., Tirelli, C., Marchetti, F., Cefalo, J., Nalesso, G., Ferranti, G., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00550-2024 · Cited by 22
Endoplasmic reticulum stress in acute lung injury and pulmonary fibrosis
Sun, Z., He, W., Meng, H., Li, P., & Qu, J. (2024) · The FASEB Journal · doi:10.1096/fj.202401849rr · Cited by 24
Walters, T. M., Leong, M. C. H., Montesi, S. B., Ryerson, C. J., & Khor, Y. H. (2025) · European Respiratory Review · doi:10.1183/16000617.0238-2024 · Cited by 20
Alonso-González, A., Jáspez, D., Lorenzo-Salazar, J. M., Ma, S., Strickland, E., Mychaleckyj, J. C., Kim, J. S., Huang, Y., Adegunsoye, A., Oldham, J. M., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00045-1 · Cited by 24
Brazee, P. L., Allen, N., Knipe, R. S., Redente, E. F., & Saux, C. J. L. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2649-9402 · Cited by 27
Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis
Hirasawa, Y., Abe, M., Terada, J., Sakayori, M., Suzuki, K., Yoshioka, K., Kawasaki, T., Tsushima, K., & Tatsumi, K. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101917 · Cited by 16
Erre, G. L., Sebastiani, M., Manfredi, A., Gerratana, E., Atzeni, F., Passiu, G., & Mangoni, A. A. (2021) · Drugs in Context · doi:10.7573/dic.2020-8-6 · Cited by 20
Physical activity decline is disproportionate to decline in pulmonary physiology in IPF
Prasad, J. D., Paul, E. M., Holland, A. E., Glaspole, I., & Westall, G. P. (2021) · Respirology · doi:10.1111/resp.14137 · Cited by 17
Self-citationAronson, K. I., & Suzuki, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.745908 · Cited by 21
Wu, S., Tsai, J., Pan, H., Arbiser, J. L., Elia, L., & Sheu, M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15806 · Cited by 22
Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective
Tu, H., Han, L. W., Hsu, J. C., Kamath, N., & Pan, L. (2023) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231181537 · Cited by 17
Associations of Plasma Omega-3 Fatty Acids With Progression and Survival in Pulmonary Fibrosis
Kim, J. S., Ma, S., Ma, J. Z., Huang, Y., Bonham, C. A., Oldham, J. M., Adegunsoye, A., Strek, M. E., Flaherty, K. R., Strickland, E., et al. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.09.035 · Cited by 19
Leuschner, G., Semenova, A., Mayr, C. H., Kapellos, T. S., Ansari, M., Seeliger, B., Frankenberger, M., Kneidinger, N., Hatz, R. A., Hilgendorff, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108345 · Cited by 18
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis
Simonetti, J., Ficili, M., Sgalla, G., & Richeldi, L. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2305126 · Cited by 18
Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis
Covvey, J. R., & Mancl, E. E. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014551015 · Cited by 20
Cough in interstitial lung disease
Garner, J. L., George, P. M., & Renzoni, E. A. (2015) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2015.10.009 · Cited by 19
Lee, J. S., & Fischer, A. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1139454 · Cited by 18
Nintedanib for treating idiopathic pulmonary fibrosis
Hayton, C., & Chaudhuri, N. (2016) · British Journal of Healthcare Management · doi:10.12968/bjhc.2016.22.5.250 · Cited by 17
Increased hemoglobin-oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis
Geng, X., Dufu, K., Hutchaleelaha, A., Xu, Q. R., Li, Z., Li, C.-M., Patel, M. P., Vlahakis, N. E., Lehrer‐Graiwer, J., & Oksenberg, D. (2016) · Physiological Reports · doi:10.14814/phy2.12965 · Cited by 20
Spagnolo, P. (2017) · Milestones in drug therapy · doi:10.1007/978-3-0348-0977-1_11 · Cited by 18
New treatment directions for IPF: current status of ongoing and upcoming clinical trials
Macagno, F., Varone, F., Leone, P. M., Mari, P., Panico, L., Berardini, L., & Richeldi, L. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1335601 · Cited by 19
Diagnosis of Idiopathic Pulmonary Fibrosis “Pragmatic Challenges in Clinical Practice”
Tzilas, V., Τzouvelekis, Α., Chrysikos, S., Papiris, S. A., & Bouros, D. E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00151 · Cited by 21
Petroulia, V., Funke, M., Zumstein, P., et al. (2017) · Investigative Radiology · doi:10.1097/rli.0000000000000405 · Cited by 17
Imaging biomarkers and staging in IPF
Walsh, S. L. F. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000507 · Cited by 19
The immunomodulatory role of interleukin-35 in fibrotic diseases
Luo, M., Peng, H., Chen, P., & Zhou, Y. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1564041 · Cited by 19
“On these basis, two drugs Pirfenidone [19] and Nintedanib [20] have been recently approved by US FDA for treatment of”
BackgroundInfluentialPirfenidone Therapy for Familial Pulmonary Fibrosis: A Real-Life Study
Bennett, D., Refini, R. M., Valentini, M. L., Fui, A., Fossi, A., Pieroni, M., Mazzei, M. A., & Rottoli, P. (2019) · Lung · doi:10.1007/s00408-019-00203-w · Cited by 17
Clay, E., Cristeau, O., Chafaie, R., Pinta, A., Mazaleyrat, B., & Cottin, V. (2019) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2019.1626171 · Cited by 17
Harari, S. A., Cereda, F., Pane, F., et al. (2019) · Medicina · doi:10.3390/medicina55090606 · Cited by 17
“The guidelines indicate surgical lung biopsy (SLB) for those patients suspected of having IPF who are however at minimal surgical risk.”
BackgroundInfluentialJudson, M. A. (2019) · F1000Research · doi:10.12688/f1000research.20696.1 · Cited by 19
Identification of a unique temporal signature in blood and BAL associated with IPF progression
Norman, K. C., O’Dwyer, D. N., Salisbury, M. L., DiLillo, K. M., Lama, V. N., Xia, M., Gurczynski, S. J., White, E. S., Flaherty, K. R., Martínez, F. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67956-w · Cited by 17
McLean, A. E. B., Webster, S. E., Fry, M., Lau, E., Corte, P., Torzillo, P. J., Troy, L. K., Jo, H. E., Geis, M., Rhodes, J. E., et al. (2020) · Respirology · doi:10.1111/resp.13913 · Cited by 19
The Treatment of Lung Involvement in Systemic Sclerosis
Ruaro, B., Confalonieri, M., Matucci‐Cerinic, M., Salton, F., Confalonieri, P., Santagiuliana, M., Citton, G. M., Baratella, E., & Bruni, C. (2021) · Pharmaceuticals · doi:10.3390/ph14020154 · Cited by 19
Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review
Bos, S., Sadeleer, L. D., Vanstapel, A., Beeckmans, H., Sacreas, A., Yserbyt, J., Wuyts, W. A., & Vos, R. (2021) · European Respiratory Review · doi:10.1183/16000617.0050-2021 · Cited by 26
Wang, P., & Xu, Z. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01645-w · Cited by 17
Interstitial lung abnormalities – current knowledge and future directions
Axelsson, G. T., & Guðmundsson, G. (2021) · European Clinical Respiratory Journal · doi:10.1080/20018525.2021.1994178 · Cited by 16
Yang, M. X., Yin, E. G., Xu, Y., Liu, Y.-J., Li, T., Dong, Z., & Tai, W. (2022) · Bioengineered · doi:10.1080/21655979.2022.2044252 · Cited by 17
Insights gained in the pathology of lung disease through single‐cell transcriptomics
Carraro, G., & Stripp, B. R. (2022) · The Journal of Pathology · doi:10.1002/path.5971 · Cited by 17
Ginkgolic acid improves bleomycin‐induced pulmonary fibrosis by inhibiting SMAD4 SUMOylation
Yu, L., Bian, X., Zhang, C., Wu, Z., Huang, N., Yang, J., Jin, W., Feng, Z., Li, D., Huo, X., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8002566 · Cited by 19
Caro, F. M., Buendía-Roldán, I., Noriega, L., Alberti, M. L., Amaral, A. F., Arbo, G., Auteri, S. J., Bermúdez, A., Curbelo, P., Verduzco, M. D. J. D., et al. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2022.04.007 · Cited by 20
O’Flaherty, B. M., Matar, C. G., Wakeman, B. S., Garcia, A., Wilke, C. A., Courtney, C. L., Moore, B. B., & Speck, S. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135719 · Cited by 18
Proton Pump Inhibitors in IPF: A Call for Clinical Trials
Ghebre, Y. T. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00499 · Cited by 21
Transforming growth factor β1 alters the 3′-UTR of mRNA to promote lung fibrosis
Ko, J., Mills, T., Huang, J., Chen, N., Mertens, T. C. J., Collum, S. D., Lee, G., Xiang, Y., Han, L., Zhou, Y., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009148 · Cited by 18
Hermansky-Pudlak syndrome-2 alters mitochondrial homeostasis in the alveolar epithelium of the lung
Cuevas-Mora, K., Roque, W., Shaghaghi, H., Gochuico, B. R., Rosas, I. O., Summer, R. S., & Romero, F. (2021) · Respiratory Research · doi:10.1186/s12931-021-01640-z · Cited by 16
Sullivan, D. I., Jiang, M., Hinchie, A. M., Roth, M. G., Bahudhanapati, H., Nouraie, M., Liu, J., McDyer, J. F., Mallampalli, R. K., Zhang, Y., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.600626 · Cited by 16
Zang, C., Zheng, Y., Wang, Y., & Li, L. (2021) · European journal of medical research · doi:10.1186/s40001-021-00601-y · Cited by 22
“NA King 2014 Nausea (36.0%), rash (28.1%), headache (25.9%), cough (25.2%), diarrhea (22.3”
BackgroundInfluentialYang, Y., dos Santos, D. M., Pantano, L., Knipe, R. S., Abe, E. A., Logue, A., Pronzati, G., Black, K. E., Spinney, J. J., Giacona, F. L., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0428oc · Cited by 20
Glucocorticoid Therapy in Respiratory Illness: Bench to Bedside
Amratia, D., Viola, H., & Ioachimescu, O. C. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002161 · Cited by 21
Invadosome Formation by Lung Fibroblasts in Idiopathic Pulmonary Fibrosis
Lebel, M., Cliché, D. O., Charbonneau, M., Adam, D., Brochiero, E., Dubois, C. M., & Cantin, A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010499 · Cited by 16
“Of n te, the capacity of IPF fibroblasts to form invadosomes was not associated with fibronectin expression (Figure S1B) or with FVC clinical measures or smoking status (Figure S2A-B).”
BackgroundInfluentialKnockdown of FBLN2 suppresses TGF-β1-induced MRC-5 cell migration and fibrosis by downregulating VTN
Zhang, Y., Zhang, W., Zhang, R., & Xia, Y. (2022) · Tissue and Cell · doi:10.1016/j.tice.2022.102005 · Cited by 19
Kang, J., Chung, M. P., Park, M. S., Oh, I., Lee, H. B., Kim, Y. W., Park, J. S., Uh, S. T., Kim, Y. S., Jegal, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1025947 · Cited by 19
“All patients were diagnosed with IPF at the host site based on the ATS/ERS/ Japanese Respiratory Society/Latin American Thoracic Association guidelines (Raghu et al., 2011).”
BackgroundInfluentialExpert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease
Dai, H., Ma, F., Ren, Y., Chen, S.-S., & Li, Y. (2023) · Current Medical Science · doi:10.1007/s11596-022-2693-2 · Cited by 23
Palliative care for interstitial lung disease: A nationwide survey of pulmonary specialists
Fujisawa, T., Akiyama, N., Morita, T., Koyauchi, T., Matsuda, Y., Mori, M., Miyashita, M., Tachikawa, R., Tomii, K., Tomioka, H., et al. (2023) · Respirology · doi:10.1111/resp.14493 · Cited by 17
Zhao, C., Yin, Y., Zhu, C., Zhu, M., Ji, T., Li, Z., & Cai, J. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102071 · Cited by 18
Vitamin D and idiopathic pulmonary fibrosis: a two-sample mendelian randomization study
Lin, T., Zhou, F., Mao, H., Xie, Z., & Jin, Y. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02589-z · Cited by 17
Gerokonstantis, D. T., Mantzourani, C., Gkikas, D., Wu, K., Hoang, H. N., Triandafillidi, I., Barbayianni, I., Kanellopoulou, P., Kokotos, A. C., Moutevelis‐Minakakis, P., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01422 · Cited by 16
Emerging Treatments for Childhood Interstitial Lung Disease
Bernardinello, N., Griese, M., Borie, R., & Spagnolo, P. (2023) · Pediatric Drugs · doi:10.1007/s40272-023-00603-9 · Cited by 20
Guan, Y., Zhang, J., Cai, X., Cai, Y., Song, Z., Huang, Y., Qian, W., Pan, Z., & Zhang, X. (2023) · Gene · doi:10.1016/j.gene.2023.148040 · Cited by 20
Yang, C., Rubin, L., Yu, X., Lazarovici, P., & Zheng, W. (2024) · Medicinal Research Reviews · doi:10.1002/med.22014 · Cited by 18
Development, Progression, and Mortality of Suspected Interstitial Lung Disease in COPDGene
Rose, J. A., Tukpah, A.-M. C., Cutting, C. C., Wada, N., Nishino, M., Moll, M. R., Kalra, S., Choi, B., Lynch, D. A., Raby, B. A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202402-0313oc · Cited by 19
Luzina, I. G., Lockatell, V., Todd, N. W., Kopach, P., Pentikis, H. S., & Atamas, S. P. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.224675 · Cited by 17
“…such as rheumatoid arthritis (Marigliano et al., 2013) and idiopathic inflammatorymyopathy (Hallowell et al., 2014); despite recent advances in developing new therapies (King et al., 2014; Richeldi et al., 2014), finding a cure and improving existing therapies for ILD is still challenging.”
BackgroundBeyond TGFβ – Novel ways to target airway and parenchymal fibrosis
Boorsma, C. E., Dekkers, B. G. J., van Dijk, E. M., Kumawat, K., Richardson, J., Burgess, J. K., & John, A. E. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2014.08.009 · Cited by 18
Zimmer, A. S., & Steeg, P. S. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1226-2 · Cited by 19
“Positive phase III trial data was recently reported in idiopathic pulmonary fibrosis with pirfenidone, with a tolerable toxicity profile, the most common side effects being skin and gastrointestinal related [129].”
BackgroundJo, H. E., Prasad, J. D., Troy, L. K., Mahar, A. M., Bleasel, J. F., Ellis, S. J., Chambers, D. C., Holland, A. E., Lake, F., Keir, G. J., et al. (2017) · The Medical Journal of Australia · doi:10.5694/mja17.00799 · Cited by 16
Self-citationOhkubo, H., Taniguchi, H., Kondoh, Y., Yagi, M., Furukawa, T., Johkoh, T., Arakawa, H., Fukuoka, J., & Niimi, A. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9508-17 · Cited by 18
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.